Overview

First Step With Singulair® Therapy (0476-323)

Status:
Completed

Trial end date:
2003-12-01

Target enrollment:

Participant gender:

Summary

In adult patients with mild persistent asthma, singulair® 10 mg will be at least as effective as low dose Inhaled Corticosteroids (ICS) in improving asthma symptom control or satisfaction over a 6 week comparison period.

Phase:

Phase 4

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Fluticasone
Montelukast